TITLE

RISKS AND BENEFITS OF BIOLOGIC THERAPY FOR INFLAMMATORY BOWEL DISEASES

AUTHOR(S)
D'Haens, Geert
PUB. DATE
May 2007
SOURCE
Gut;May2007, Vol. 56 Issue 5, p725
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the advantages and disadvantages of biologic therapy for inflammatory bowel diseases. According to the author, biologics are associated with certain toxicities and should only be used in patients who need the treatment. He mentions that patients should be aware of the toxicity profile and of the appropriate guidelines to prevent and treat complications.
ACCESSION #
25298740

 

Related Articles

  • Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease. Mi Jin Kim; Yon Ho Choe // Pediatric Gastroenterology, Hepatology & Nutrition;Jun2013, Vol. 16 Issue 2, p65 

    Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal...

  • Adverse Reaction Research.  // Reactions Weekly;12/5/2009, Issue 1281, p5 

    This section discusses various medical-related research. A research discovered that the use of azathioprine in inflammatory bowel disease (IBD) increases the risk of developing blepharitis. One study found that the incidence of thrombocytopenia linked with linezolid is low among veterans....

  • IBD medications linked to nonmelanoma skin cancer.  // Reactions Weekly;12/5/2009, Issue 1281, p4 

    The article focuses on a research which examined the link between inflammatory bowel disease (IBD) medication and nonmelanoma skin cancer. The study included 387 Crohn's disease and 355 ulcerative colitis. It found that the use of biologics increases the risk of nonmelanoma skin cancer in...

  • CAN THE NEED FOR AZATHIPRINE BE PREDICTED AT THE TIME OF INITIAL PRESENTATION WITH IBD?  // Archives of Disease in Childhood;Apr2003 Supplement, Vol. 88, pA14 

    Presents an abstract of the study 'Can the Need for Azathioprine be Predicted at the Time of Initial Presentation With IBD?,' by H. Mossop, P. Davies and M.S. Murphy, presented at the 7th Spring Meeting of the Royal College of Paediatrics and Child Health.

  • Successful intervention for IBS. Ruckert, Linden // Pulse;9/30/2002, Vol. 62 Issue 37, p44 

    Examines inflammatory bowel syndrome. Percentage of the population affected with the disease; Disturbance of gut motility; Signs and symptoms of the disease; Association of the disease with anxiety and depression; Medication of choice.

  • Excessive reports of isotretinoin-associated IBD by attorneys.  // Reactions Weekly;6/22/2013, Issue 1458, p3 

    This article reports on the increase in the number of reports on isotretinoin-associated inflammatory bowel disease (IBD) between January 2003 and December 2011.

  • Golimumab.  // Reactions Weekly;1/14/2012, Issue 1384, p29 

    The article describes three cases of exacerbation of inflammatory bowel disease which developed while patients were receiving treatment with golimumab.

  • 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Present, Daniel H.; Meltzer, Stephen J.; Krumholz, Michael P.; Wolke, Anita; Korelitz, Burton I.; Present, D H; Meltzer, S J; Krumholz, M P; Wolke, A; Korelitz, B I // Annals of Internal Medicine;10/15/89, Vol. 111 Issue 8, p641 

    We assess toxicity related to 6-mercaptopurine in the treatment of inflammatory bowel disease by reporting our experience with 396 patients (120 patients with ulcerative colitis, 276 with Crohn disease) observed over 18 years. Follow-up data for a mean period of 60.3 months were obtained for 90%...

  • Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. Uchiyama, Kan; Nakamura, Makoto; Kubota, Takahiro; Yamane, Tateki; Fujise, Kiyotaka; Tajiri, Hisao // Journal of Gastroenterology;2009, Vol. 44 Issue 3, p197 

    The main cause of azathioprine (AZA)/6-mercaptopurine (6MP)-induced adverse reactions is a reduction in the activities of the metabolizing enzymes thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA). Adverse reactions develop at a high frequency in Japanese...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics